• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物与脂质比例对脂质体阿霉素制剂中药物释放特性及脂质体完整性的影响。

Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations.

作者信息

Johnston Michael J W, Edwards Katarina, Karlsson Goran, Cullis Pieter R

机构信息

Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

J Liposome Res. 2008;18(2):145-57. doi: 10.1080/08982100802129372.

DOI:10.1080/08982100802129372
PMID:18569449
Abstract

Recent studies have shown that the release properties of vincristine encapsulated in large unilamellar vesicles (LUV) can be regulated by varying the drug-to-lipid (D/L) ratio. In this work it is shown that the drug-to-lipid ratio technique for regulating drug release also applies to doxorubicin encapsulated in LUV. In particular it is shown that the half-times (T(1/2)) for doxorubicin release from distearoylphosphatidylcholine (DSPC)/cholesterol LUV in vitro can be increased more than six-fold by increasing the D/L ratio from 0.05 (wt/wt) to 0.39 (wt/wt). This behavior is consistent with the behavior expected for drugs that precipitate following accumulation into liposomes. It is shown that the release properties of ciprofloxacin--a drug that does not precipitate following accumulation into LUV--are not affected by the D/L ratio. It is also shown that the crystalline intravesicular doxorubicin precipitates observed as the D/L ratio is raised from 0.05 to 0.46 adopt increasingly unusual morphologies. Linear crystals are observed at lower D/L values, however triangular and rectangular variations are observed as the D/L ratio is increased, and induce considerable distortion in vesicle morphology. It is noted that trapping efficiency following uptake of external doxorubicin into LUV is reduced from nearly 100% at a D/L ratio of 0.05 (wt/wt) to less than 70% at an (initial) D/L ratio of 0.8 (wt/wt). It is suggested that this arises, at least in part, from membrane-disrupting effects of internal drug crystals as they increase in size.

摘要

最近的研究表明,包裹在大单层囊泡(LUV)中的长春新碱的释放特性可通过改变药物与脂质(D/L)比来调节。在这项工作中表明,调节药物释放的药物与脂质比技术也适用于包裹在LUV中的阿霉素。特别表明,通过将D/L比从0.05(重量/重量)增加到0.39(重量/重量),阿霉素从二硬脂酰磷脂酰胆碱(DSPC)/胆固醇LUV体外释放的半衰期(T(1/2))可增加超过六倍。这种行为与预期的药物行为一致,即药物在积累到脂质体中后会沉淀。结果表明,环丙沙星(一种在积累到LUV中后不会沉淀的药物)的释放特性不受D/L比的影响。还表明,随着D/L比从0.05提高到0.46,观察到的囊泡内结晶阿霉素沉淀呈现出越来越不寻常的形态。在较低的D/L值下观察到线性晶体,然而随着D/L比增加,观察到三角形和矩形变体,并导致囊泡形态发生相当大的扭曲。值得注意的是,外部阿霉素被摄取到LUV中的捕获效率从D/L比为0.05(重量/重量)时的近100%降低到(初始)D/L比为0.8(重量/重量)时的不到70%。有人认为,这至少部分是由于内部药物晶体尺寸增加时对膜的破坏作用。

相似文献

1
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations.药物与脂质比例对脂质体阿霉素制剂中药物释放特性及脂质体完整性的影响。
J Liposome Res. 2008;18(2):145-57. doi: 10.1080/08982100802129372.
2
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.囊泡大小、脂质组成及药物与脂质比例对小鼠脂质体阿霉素生物活性的影响。
Cancer Res. 1989 Nov 1;49(21):5922-30.
3
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.通过改变脂质体长春新碱制剂中的药物与脂质比例,可以实现治疗上优化的药物释放速率。
Biochim Biophys Acta. 2006 Jan;1758(1):55-64. doi: 10.1016/j.bbamem.2006.01.009. Epub 2006 Feb 3.
4
Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.由冻干脂质体组成的脂质体阿霉素制剂试剂盒。
Anticancer Res. 2003 Jan-Feb;23(1A):439-42.
5
Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients.影响含氨基药物在呈现跨膜pH梯度的大单层囊泡中的摄取和保留的因素。
Biochim Biophys Acta. 1999 Jan 12;1416(1-2):1-10. doi: 10.1016/s0005-2736(98)00204-1.
6
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.药物释放速率会影响聚乙二醇化脂质体阿霉素制剂在小鼠乳腺癌模型中的药代动力学、生物分布、治疗活性及毒性。
Biochim Biophys Acta. 2004 May 27;1663(1-2):167-77. doi: 10.1016/j.bbamem.2004.03.006.
7
Formation of transition metal-doxorubicin complexes inside liposomes.脂质体内过渡金属-阿霉素复合物的形成。
Biochim Biophys Acta. 2002 Sep 20;1565(1):41-54. doi: 10.1016/s0005-2736(02)00507-2.
8
Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.制备技术对用于透皮给药的包封酮洛芬 - 环糊精复合物的脂质体性质的影响。
Int J Pharm. 2006 Apr 7;312(1-2):53-60. doi: 10.1016/j.ijpharm.2005.12.047. Epub 2006 Feb 15.
9
A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.研究胆固醇和磷脂酰胆碱在脂质体阿霉素各种特性中的作用:从脂质体制备到治疗。
Int J Pharm. 2018 Nov 15;551(1-2):300-308. doi: 10.1016/j.ijpharm.2018.09.047. Epub 2018 Sep 20.
10
Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.高效保留包封的阿霉素(DXR)于血液中的pH敏感脂质体的研发。
Int J Pharm. 2006 Feb 17;309(1-2):94-100. doi: 10.1016/j.ijpharm.2005.11.010. Epub 2005 Dec 20.

引用本文的文献

1
Development of Liposomal Formulations for 1,4-bis-L/L Methionine-Conjugated Mitoxantrone-Amino Acid Conjugates to Improve Pharmacokinetics and Therapeutic Efficacy.用于1,4-双-L/L-甲硫氨酸共轭米托蒽醌-氨基酸共轭物的脂质体制剂的研发,以改善药代动力学和治疗效果。
Pharmaceutics. 2025 Sep 21;17(9):1226. doi: 10.3390/pharmaceutics17091226.
2
Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications.从脂质体到立方脂质体:脂质纳米载体的演变及其在生物医学中的前沿应用。
ACS Appl Bio Mater. 2024 May 20;7(5):2677-2694. doi: 10.1021/acsabm.4c00153. Epub 2024 Apr 13.
3
Inner leaflet cationic lipid increases nucleic acid loading independently of outer leaflet lipid charge in asymmetric liposomes.
不对称脂质体中外叶带电荷的阳离子脂质对内叶带的核酸负载增加独立于外叶带脂质的电荷。
Methods. 2023 Nov;219:16-21. doi: 10.1016/j.ymeth.2023.08.015. Epub 2023 Sep 7.
4
Cubosomes in Drug Delivery-A Comprehensive Review on Its Structural Components, Preparation Techniques and Therapeutic Applications.药物递送中的立方液晶纳米粒——关于其结构成分、制备技术及治疗应用的全面综述
Biomedicines. 2023 Apr 7;11(4):1114. doi: 10.3390/biomedicines11041114.
5
Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer.载尼拉帕利和多柔比星的叶酸受体靶向纳米粒:治疗高级别浆液性卵巢癌的潜在候选药物。
Sci Rep. 2023 Feb 24;13(1):3226. doi: 10.1038/s41598-023-28424-3.
6
Quality by Design Approach in Liposomal Formulations: Robust Product Development.质量源于设计在脂质体制剂中的应用:稳健的产品开发。
Molecules. 2022 Dec 20;28(1):10. doi: 10.3390/molecules28010010.
7
Cardiolipin for Enhanced Cellular Uptake and Cytotoxicity of Thermosensitive Liposome-Encapsulated Daunorubicin toward Breast Cancer Cell Lines.载脂蛋白磷脂用于增强热敏脂质体包封的柔红霉素对乳腺癌细胞系的细胞摄取和细胞毒性。
Int J Mol Sci. 2022 Oct 4;23(19):11763. doi: 10.3390/ijms231911763.
8
pH-Sensitive Liposomes for Enhanced Cellular Uptake and Cytotoxicity of Daunorubicin in Melanoma (B16-BL6) Cell Lines.用于增强柔红霉素在黑色素瘤(B16 - BL6)细胞系中的细胞摄取及细胞毒性的pH敏感脂质体
Pharmaceutics. 2022 May 26;14(6):1128. doi: 10.3390/pharmaceutics14061128.
9
Structural Characterization Study of a Lipid Nanocapsule Formulation Intended for Drug Delivery Applications Using Small-Angle Scattering Techniques.采用小角散射技术对一种用于药物传递应用的脂质纳米胶囊制剂的结构特征进行研究。
Mol Pharm. 2022 Apr 4;19(4):1068-1077. doi: 10.1021/acs.molpharmaceut.1c00648. Epub 2022 Feb 28.
10
A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy.辛伐他汀-阿霉素脂质体的开发筛选研究,一种在结肠癌治疗中具有未来前景的联合制剂。
Pharmaceutics. 2021 Sep 22;13(10):1526. doi: 10.3390/pharmaceutics13101526.